Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
Katodritou E et al. Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6.

Primary plasma cell leukemia in the era of novel agents for myeloma – a multicenter retrospective analysis of outcome.
Ganzel C et al. Leuk Res. 2018 Mar 1;68:9-14. doi: 10.1016/j.leukres.2018.02.010. [Epub ahead of print].

A case report of POEMS syndrome with renal involvement as immunotactoid glomerulopathy.
Wang Y et al. Medicine (Baltimore). 2018 Mar;97(9):e9920. doi: 10.1097/MD.0000000000009920.

Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
Tovar N et al. Amyloid. 2018 Feb 26:1-7. doi: 10.1080/13506129.2018.1443439. [Epub ahead of print].

A functional assay to identify amyloidogenic light chains.
Martin EB et al. Amyloid. 2018 Mar 23:1-8. doi: 10.1080/13506129.2018.1456425. [Epub ahead of print].

Quantification of Number of CD38 Sites on Bone Marrow Plasma Cells in Patients with Light Chain Amyloidosis and Smoldering Multiple Myeloma.
Kriegsmann K et al. Cytometry B Clin Cytom. 2018 Mar 25. doi: 10.1002/cyto.b.21636. [Epub ahead of print].

Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma.
Hildebrandt GC et al. Br J Haematol. 2018 Mar 24. doi: 10.1111/bjh.15095. [Epub ahead of print].